Posted on 02/02/2010 in Scientific Life Technologies, the company forged following the merger between Invitrogen and Applied Biosystems, has revealed its full-year financial results for 2009.
The firm's non-generally accepted accounting principles revenue for the fourth quarter was $874 million (547.9 million pounds), while this figure stood at $3.30 billion for the full year.
This represents a rise of five per cent over the $3.14 billion reported for the whole of 2008.
Gregory Lucier, chairman and chief executive officer of Life Technologies, said he is "very pleased" with the organisation's organic growth.
"Moving forward, we aim to leverage those strengths to further expand our position in areas such as sequencing, applied markets and clinical applications," he furthered.
Last week, Life Technologies announced the launch of its latest piece of equipment - the SOLiD 4 Sequencing System.
It can generate a maximum of 100 gigabases of mappable sequence data per run for $6,000 per genome.Other news stories from 02/02/2010
Read more in the Zenopa News Archive
How this news is generated
|
